Furthermore, 4 out of 9 male patients showed substantial tracer uptake in the prostate, for which further analysis was recommended: one of these patients deceased due to progressive PDAC before further analysis; another patient entered routine follow-up of prostate-specific antigen (PSA) levels; one patient was treated with bicalutamide hormonal therapy and then entered follow-up; and another patient was finally diagnosed with a cT2/iT3aN0M0 high risk (Gleason 9) prostate carcinoma. This evidence concerns the gene KLK3 and prostate carcinoma.